- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
DETERMINATION OF EPSTEIN-BARR VIRUS (EBV) DNA LOAD AS A BIOMARKER TO FOLLOW UP EBV RELATED HODGKIN’S AND NON HODGKIN’S LYMPHOMA PATIENTS USING QUANTITATIVE COMPETITIVE POLYMERASE CHAIN REACTION TECHNIQUE | ||
| IRAQI JOURNAL OF MEDICAL SCIENCES | ||
| Article 1, Volume 9, Issue 1, 2011, Pages 61-73 | ||
| Authors | ||
| Khudair J. Al-Rawak; Nidhal AM. Mohammed; Elham A. Alaswad | ||
| Abstract | ||
| Background: The Epstein -Barr virus (EBV) is the first human virus implicated in the carcinogenesis. EBV contributes to the carcinogenesis like Hodgkin's Lymphoma (HL) and Non Hodgkin’s Lymphoma (NHL). Objective: Quantitative Competitive Polymerase Chain Reaction (QC-PCR) and ELISA was used to quantitate the EBV DNA load in blood samples of HL and NHL patients pre and post therapy. Methods: EBV DNA extracted from blood samples of 18 HL and NHL patients pre and post therapy, 9 apparently healthy controls used to quantify the EBV DNA load. Quantitative Competitive Polymerase Chain Reaction (QC-PCR) and ELISA were used to quantify EBV DNA load. Wild EBV DNA (WT) obtained by Transformation of Escherichia coli MM 294 with Wild type (WT) DNA plasmid pGEMBamHI-K. Results: EBV DNA load in controls was found to be 7-1.99 × 103 in HL and NHL patients, while in patients it's ranged from zero to 1.936×109 copy numbers per ml of blood. High EBV load with the range of 10715(1.071×104) to 1936421960 (1.936×109) above cut-off value was detected in 66.7% of HL and 5861(5.86×103)-50118(5.01×104) copies/ml blood in 44.5 % of NHL patients pretherapy. After chemotherapy, 60% of HL patients and 100% of HL patients with high EBV load showed significant response. Low viral load was found in 44.45% of patients. Only 55% of lymphoma patients with high EBV load, after chemotherapy 16.6% of them continue to have high EBV DNA load compared to the control group, 38.3% of the patients showed response to chemotherapy when their viral load decreased below cut off value. While 11.1 % continue to have high DNA load. One patient (5.5%) showed an elevated EBV load after completion of chemotherapy. Conclusions: EBV DNA load estimated by Quantitative Competitive Polymerase Chain Reaction considered as valuable promising tumor biomarker in the diagnosis and monitoring of EBV related HL and NHL patients. Key words: Quantitative Competitive Polymerase Chain Reaction (QC-PCR), Epstein-Barr virus (EBV), Viral DNA load, Hodgkin’s (HL) and non Hodgkin’s Lymphoma (NHL) Patients. | ||
| Keywords | ||
| Quantitative Competitive Polymerase Chain Reaction; PCR; Epstein; Barr virus; Viral DNA load; Hodgkin | ||
|
Statistics Article View: 177 PDF Download: 159 |
||